Core Viewpoint - The announcement from Valiant Biopharma-B (09887.HK) highlights significant progress in the clinical research of LBL-034, a bispecific antibody targeting GPRC5D/CD3, with promising Phase I data and the successful treatment of the first patient in Phase II trials [1] Group 1: Clinical Trial Results - The Phase I trial of LBL-034 involved over 50 patients with relapsed/refractory multiple myeloma, showing positive efficacy signals and good safety at a dose of 1,200 μg/kg [1] - The overall response rate was robust, with a higher rate of complete response or deeper responses (≥CR) and minimal residual disease (MRD) negativity compared to current standard therapies [1] - Notably, significant efficacy was observed in the difficult-to-treat extramedullary (EMD) myeloma patient subgroup [1] Group 2: Future Developments - Detailed results from the study are set to be presented at the 2025 American Society of Hematology (ASH) annual meeting [1] - The Phase II trial is a multicenter, single-arm, multi-cohort study led by Professor Lu Jin from Peking University People's Hospital, involving over 20 hospitals nationwide [1] - The aim of the Phase II trial is to evaluate the efficacy and safety of LBL-034 in various relapsed/refractory plasma cell tumors [1]
维立志博-B(09887.HK)：LBL-034 II期试验首例患者用药